Inside Step Pharma’s Pan‑Cancer Ambition

Andrew Parker, CEO at Step Pharma, outlined the company’s “pipeline in a product” strategy as it seeks to develop a targeted approach to blood cancers and solid tumors by inhibiting CTSP1 enzyme. #clinicalstrategy #oncology

Episode metadata supplied by the publisher feed · Published Apr 7, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Inside Step Pharma’s Pan‑Cancer Ambition

0:00 28:53

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Citeline Podcasts?

This episode is 28 minutes long.

When was this Citeline Podcasts episode published?

This episode was published on April 7, 2026.

Can I download this Citeline Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!